2025
SJR Q1
JCR Q2 · 3,8
102 eşleşen makale
SCIE
Dergi ayrıntısı
NeuroToxicology
- Yayıncı
- Elsevier B.V.
- Ülke
- Netherlands · Western Europe
- Tür
- journal
- ISSN
-
0161813X18729711
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 1,026
- Quartile Q1
- H-Index 141
- Atıf/yayın 3,98
- Doküman (3y) 380
- Atıf (3y) 1.790
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 3,8
- 5Y JIF 4,3
- JCI 0,98
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Neuroscience (miscellaneous) Q2
- Toxicology Q1
Alanlar
- Neuroscience
- Pharmacology, Toxicology and Pharmaceutics
WoS kategorileri
- Neurosciences | Pharmacology & Pharmacy | Toxicology
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q2 | 1,026 | 3,8 | 4,3 | 0,98 | Q1 | 141 |
| 2024 | Q1 | Q1 | 0,979 | 3,9 | 4,1 | 1,03 | Q1 | 137 |
| 2023 | Q2 | Q2 | 0,829 | 3,4 | 3,6 | 0,98 | Q1 | 137 |
| 2022 | Q2 | Q2 | 0,795 | 3,4 | 3,8 | 1 | Q1 | 137 |
| 2021 | Q1 | Q2 | 0,805 | 4,4 | 4,4 | 1,07 | Q1 | 137 |
| 2020 | Q1 | Q2 | 1,06 | 4,3 | 4,4 | 1,07 | Q1 | 137 |
| 2019 | Q1 | Q2 | 0,933 | 3,1 | 3,4 | 1,06 | Q1 | 137 |
| 2018 | — | Q2 | — | 3,3 | 3,6 | 1,06 | Q1 | — |
| 2017 | Q2 | Q2 | 1,017 | 3,1 | 3,6 | 1,03 | Q1 | 137 |
| 2016 | Q1 | Q2 | 1,148 | 3,1 | 3,5 | — | — | 137 |
| 2015 | Q1 | Q2 | 1,274 | 2,7 | 3,1 | — | — | 137 |
| 2014 | Q1 | Q1 | 1,293 | 3,4 | 3,3 | — | — | 137 |
| 2013 | Q2 | Q2 | 1,027 | 3,1 | 3,3 | — | — | 137 |
| 2012 | Q2 | Q2 | 0,982 | 2,7 | 3,3 | — | — | 137 |
| 2011 | Q1 | Q2 | 1,225 | 3,1 | 3,4 | — | — | 137 |
| 2010 | Q1 | Q2 | 1,128 | 2,9 | 3,1 | — | — | 137 |
| 2009 | — | Q2 | — | 2,9 | 3,1 | — | — | — |
| 2008 | — | Q2 | — | 2,4 | 2,6 | — | — | — |
| 2007 | — | Q1 | — | 3 | 3,1 | — | — | — |
| 2006 | — | Q1 | — | 2,7 | — | — | — | — |
| 2005 | — | Q1 | — | 2,6 | — | — | — | — |
| 2004 | — | Q1 | — | 2,5 | — | — | — | — |
| 2003 | — | Q2 | — | 1,9 | — | — | — | — |
| 2002 | — | Q2 | — | 1,7 | — | — | — | — |
| 2001 | — | Q2 | — | 1,6 | — | — | — | — |
| 2000 | — | Q2 | — | 1,7 | — | — | — | — |
| 1999 | — | Q2 | — | 1,3 | — | — | — | — |
| 1998 | — | Q2 | — | 1,2 | — | — | — | — |
| 1997 | — | Q1 | — | 1,7 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | NEUROSCIENCES | SCIE | Q2 | Q2 | 118/330 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 116/356 |
| 2025 | TOXICOLOGY | SCIE | Q2 | Q1 | 32/106 |
| 2024 | NEUROSCIENCES | SCIE | Q2 | Q2 | 86/314 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 88/352 |
| 2024 | TOXICOLOGY | SCIE | Q2 | Q1 | 27/106 |
| 2023 | NEUROSCIENCES | SCIE | Q2 | Q2 | 116/310 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 105/354 |
| 2023 | TOXICOLOGY | SCIE | Q2 | Q1 | 35/106 |
| 2022 | NEUROSCIENCES | SCIE | Q2 | Q2 | 136/272 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 125/278 |
| 2022 | TOXICOLOGY | SCIE | Q2 | Q1 | 34/94 |
| 2021 | NEUROSCIENCES | SCIE | Q2 | Q2 | 112/275 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 100/279 |
| 2021 | TOXICOLOGY | SCIE | Q2 | Q1 | 26/94 |
| 2020 | NEUROSCIENCES | SCIE | Q2 | Q2 | 103/273 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 93/276 |
| 2020 | TOXICOLOGY | SCIE | Q2 | Q1 | 26/93 |
| 2019 | NEUROSCIENCES | SCIE | Q2 | Q2 | 131/272 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 105/271 |
| 2019 | TOXICOLOGY | SCIE | Q2 | Q1 | 40/92 |
| 2018 | NEUROSCIENCES | SCIE | Q2 | Q2 | 113/267 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 85/267 |
| 2018 | TOXICOLOGY | SCIE | Q2 | Q1 | 32/93 |
| 2017 | NEUROSCIENCES | SCIE | Q2 | Q2 | 128/261 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 92/261 |
| 2017 | TOXICOLOGY | SCIE | Q2 | Q2 | 34/94 |
| 2016 | NEUROSCIENCES | SCIE | Q2 | — | 113/259 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 79/257 |
| 2016 | TOXICOLOGY | SCIE | Q2 | — | 29/92 |
| 2015 | NEUROSCIENCES | SCIE | Q2 | — | 126/256 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 91/255 |
| 2015 | TOXICOLOGY | SCIE | Q2 | — | 32/90 |
| 2014 | NEUROSCIENCES | SCIE | Q2 | — | 94/252 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 65/255 |
| 2014 | TOXICOLOGY | SCIE | Q1 | — | 20/88 |
| 2013 | NEUROSCIENCES | SCIE | Q2 | — | 120/252 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 74/256 |
| 2013 | TOXICOLOGY | SCIE | Q2 | — | 26/87 |
| 2012 | NEUROSCIENCES | SCIE | Q3 | — | 139/252 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 100/261 |
| 2012 | TOXICOLOGY | SCIE | Q2 | — | 33/85 |
| 2011 | NEUROSCIENCES | SCIE | Q2 | — | 105/244 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 74/261 |
| 2011 | TOXICOLOGY | SCIE | Q2 | — | 22/83 |
| 2010 | NEUROSCIENCES | SCIE | Q2 | — | 112/239 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 80/252 |
| 2010 | TOXICOLOGY | SCIE | Q2 | — | 28/83 |
| 2009 | NEUROSCIENCES | SCIE | Q2 | — | 109/231 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 79/237 |
| 2009 | TOXICOLOGY | SCIE | Q2 | — | 23/77 |
| 2008 | NEUROSCIENCES | SCIE | Q3 | — | 131/221 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 100/219 |
| 2008 | TOXICOLOGY | SCIE | Q2 | — | 29/75 |
| 2007 | NEUROSCIENCES | SCIE | Q2 | — | 74/211 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 60/205 |
| 2007 | TOXICOLOGY | SCIE | Q1 | — | 12/73 |
| 2006 | NEUROSCIENCES | SCIE | Q2 | — | 86/200 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 63/199 |
| 2006 | TOXICOLOGY | SCIE | Q1 | — | 14/76 |
| 2005 | NEUROSCIENCES | SCIE | Q2 | — | 85/200 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 59/193 |
| 2005 | TOXICOLOGY | SCIE | Q1 | — | 14/75 |
| 2004 | NEUROSCIENCES | SCIE | Q2 | — | 85/198 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 58/187 |
| 2004 | TOXICOLOGY | SCIE | Q1 | — | 17/75 |
| 2003 | NEUROSCIENCES | SCIE | Q3 | — | 114/198 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 86/185 |
| 2003 | TOXICOLOGY | SCIE | Q2 | — | 24/77 |
| 2002 | NEUROSCIENCES | SCIE | Q3 | — | 116/197 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 85/188 |
| 2002 | TOXICOLOGY | SCIE | Q2 | — | 29/76 |
| 2001 | NEUROSCIENCES | SCIE | Q3 | — | 116/198 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 74/186 |
| 2001 | TOXICOLOGY | SCIE | Q2 | — | 29/78 |
| 2000 | NEUROSCIENCES | SCIE | Q3 | — | 104/203 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 65/181 |
| 2000 | TOXICOLOGY | SCIE | Q2 | — | 21/77 |
| 1999 | NEUROSCIENCES | SCIE | Q3 | — | 123/201 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 80/175 |
| 1999 | TOXICOLOGY | SCIE | Q2 | — | 32/74 |
| 1998 | NEUROSCIENCES | SCIE | Q3 | — | 120/202 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 78/178 |
| 1998 | TOXICOLOGY | SCIE | Q2 | — | 30/71 |
| 1997 | NEUROSCIENCES | SCIE | Q3 | — | 85/150 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 47/157 |
| 1997 | TOXICOLOGY | SCIE | Q1 | — | 12/63 |